Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04494893 · ClinicalTrials.gov registry record
ImmuneRACE - Immune Response Action to COVID-19 Events
A clinical trial, sponsored by Adaptive Biotechnologies.
- Completed
- Registry status
- 808
- Enrollment target
NCT04494893 is a clinical trial that has completed, run by Adaptive Biotechnologies. The registered enrollment target is 808 participants.
The verdict
NCT04494893 has completed, sponsored by Adaptive Biotechnologies.
- COMPLETED
- Registry status
- 808 participants
- Enrollment target
Study Summary
ImmuneRACE is a study, which is designed to better understand the immune response to COVID-19. This is critically important because the immune system may be able to tell us important information about how our own bodies detect and respond to the disease that current tests cannot. De-identified data collected from this study may accelerate the development of better diagnostics for COVID-19 and improve outcomes for many.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 808 participants |
| Start Date | 2020-04-24 |
| Est. Completion | 2021-04-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04494893
The ClinicalTrials.gov registry entry for NCT04494893 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 808 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adaptive Biotechnologies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04494893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04494893 about?
NCT04494893 is a clinical study titled "ImmuneRACE - Immune Response Action to COVID-19 Events". ImmuneRACE is a study, which is designed to better understand the immune response to COVID-19. This is critically important because the immune system may be able to tell us important information about how our own bodies detect and respond to the disease that current tests cannot. De-identified data ...
What is the current status of trial NCT04494893?
This trial is currently completed. The enrollment target is 808 participants. The study started on 2020-04-24. Estimated completion is 2021-04-23.
Who is sponsoring clinical trial NCT04494893?
This trial is sponsored by Adaptive Biotechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.